The cancer researchers, who were part of a virtual ASCO meeting, heard news that UK scientists had obtained superior progression free survival in patients already taken treatment with standard chemotherapy when they combined vinorelbine along with active supportive care.

Researchers Hear News of Superior PFS in Mesothelioma Patients: Latest research about mesothelioma was presented at the ASCO virtual meeting by Dean A. Fennell, FRCP, PhD, chair of thoracic medical oncology at University of Leicester and University Hospitals of Leicester NHS Trust in the UK.

Dean A. Fennell reported that in a phase-II study, secondary chemo drug vinorelbine had offered superior PFS for patients who had relapsed after treatment with pemetrexed and cisplatin.

Dean A. Fennell stated that, “All patients with malignant pleural mesothelioma eventually relapse after standard chemotherapy with pemetrexed and cisplatin. Although, there is no standard treatment option in this patient setting.”

“Vinorelbine exhibits useful clinical activity but has not been assessed in a randomized clinical trial, despite its widespread off-label use worldwide.”

Carried Out Study in Patients with malignant pleural mesothelioma: In the phase-II carried out trial, a total of 154 patients with malignant pleural mesothelioma participated and treated between May 2016 and October 2018. 

Participated patients were randomly assigned either active support care alone or active support care along with regular dosing of vinorelbine after having their disease progress following first-line chemotherapy treatment. 

The outcomes demonstrated that median PFS of those taken treatment with vinorelbine was 4.2 months in comparison to 2.8 months for those who did not take treatment.

Conclusion: Vinorelbine is a safe and effective treatment option and should be considered for the treatment of patients with relapsed mesothelioma.

Reference: https://mesothelioma.net/mesothelioma-news/mesothelioma-patients-see-positive-results-from-secondary-chemotherapy-drug/

Leave a Reply

Your email address will not be published.

×